Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: hollebecque a. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
Bevacizumab-induced laryngeal necrosis.
Hartl DM, Bahleda R, Hollebecque A, Bosq J, Massard C, Soria JC. Hartl DM, et al. Among authors: hollebecque a. Ann Oncol. 2012 Jan;23(1):276-278. doi: 10.1093/annonc/mdr515. Epub 2011 Nov 4. Ann Oncol. 2012. PMID: 22056850 Free article. No abstract available.
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs.
Rouanne M, Massard C, Hollebecque A, Rousseau V, Varga A, Gazzah A, Neuzillet Y, Lebret T, Soria JC. Rouanne M, et al. Among authors: hollebecque a. Eur J Cancer. 2013 Jan;49(2):431-8. doi: 10.1016/j.ejca.2012.08.008. Epub 2012 Sep 6. Eur J Cancer. 2013. PMID: 22959468 Clinical Trial.
Tumor assessment criteria in phase I trials: beyond RECIST.
Levy A, Hollebecque A, Ferté C, Koscielny S, Fernandez M, Soria JC, Massard C. Levy A, et al. Among authors: hollebecque a. J Clin Oncol. 2013 Jan 20;31(3):395. doi: 10.1200/JCO.2012.46.2184. Epub 2012 Dec 17. J Clin Oncol. 2013. PMID: 23248247 No abstract available.
Targeted therapy-induced radiation recall.
Levy A, Hollebecque A, Bourgier C, Loriot Y, Guigay J, Robert C, Delaloge S, Bahleda R, Massard C, Soria JC, Deutsch E. Levy A, et al. Among authors: hollebecque a. Eur J Cancer. 2013 May;49(7):1662-8. doi: 10.1016/j.ejca.2012.12.009. Epub 2013 Jan 8. Eur J Cancer. 2013. PMID: 23312391
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
Hollebecque A, Deutsch E, Massard C, Gomez-Roca C, Bahleda R, Ribrag V, Bourgier C, Lazar V, Lacroix L, Gazzah A, Varga A, de Baere T, Beier F, Kroesser S, Trang K, Zenke FT, Klevesath M, Soria JC. Hollebecque A, et al. Invest New Drugs. 2013 Dec;31(6):1530-8. doi: 10.1007/s10637-013-0026-9. Invest New Drugs. 2013. PMID: 24077982 Clinical Trial.
[Management of the cardiovascular complications of treatment in thoracic oncology].
Ederhy S, Hollebecque A, Haddour N, Massard C, Fleury G, Ferte C, Adavane S, Besse B, Boccara F, Soria JC, Cohen A. Ederhy S, et al. Among authors: hollebecque a. Rev Mal Respir. 2014 Feb;31(2):173-80. doi: 10.1016/j.rmr.2013.09.021. Epub 2014 Jan 31. Rev Mal Respir. 2014. PMID: 24602684 Review. French.
220 results